National cancer institute-national heart, lung and blood institute/pediatric blood and marrow transplant consortium first international consensus conference on late effects after pediatric hematopoietic cell transplantation: Long-term organ damage and dysfunction

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1573-1584

  Nieder, Michael L ^a   McDonald, George B ^b   Kida, Aiko ^b   Hingorani, Sangeeta ^c,g   Armenian, Saro H ^d   Cooke, Kenneth R ^e   Pulsipher, Michael A ^f   Baker, K Scott ^g  

^a JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d City of Hope ^*  (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cardiac toxicity; Pediatric allogeneic transplantation; Pediatric autologous transplantation; Pulmonary toxicity; Renal toxicity

Indexed keywords

ARTICLE; CHILDHOOD DISEASE; FIBROSIS; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; INTERNATIONAL COOPERATION; KIDNEY DISEASE; LUNG COMPLICATION; MEDICAL SOCIETY; NATIONAL HEALTH ORGANIZATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MICE; NATIONAL CANCER INSTITUTE (U.S.); UNITED STATES;

EID: 80054846946     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.09.013     Document Type: Article

References (123)

1. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
2. Armand P., Kim H.T., Rhodes J., et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011, 17. 852-60.
3. Majhail N.S., Lazarus H.M., Burns L.J. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2010, 16:832-837.
4. Strasser S.I., Kowdley K.V., Sale G.E., et al. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 1998, 22:167-173.
5. Mariotti E., Angelucci E., Agostini A., et al. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol 1998, 103:916-921.
6. Lucarelli G., Angelucci E., Giardini C., et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 1993, 342:1388-1391.
7. Chotsampancharoen T., Gan K., Kasow K.A., et al. Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 2009, 13:348-352.
8. Brittenham G.M. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011, 364:146-156.
9. Angelucci E., Muretto P., Lucarelli G., et al. Treatment of iron overload in the " ex-thalassemic": report from the Phlebotomy Program. Ann NY Acad Sci 1998, 850:288-293.
10. Angelucci E., Muretto P., Lucarelli G., et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood 1997, 90:994-998. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.
11. Noetzli L.J., Carson S.M., Nord A.S., et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008, 112:2973-2978.
12. Anderson L.J., Holden S., Davis B., et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22:2171-2179.
13. Anderson L.J., Westwood M.A., Holden S., et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004, 127:348-355.
14. Delvecchio M., Cavallo L. Growth and endocrine function in thalassemia major in childhood and adolescence. J Endocrinol Invest 2010, 33:61-68.
15. Toumba M., Sergis A., Kanaris C., et al. Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev 2007, 5:642-648.
16. De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res 2002, 58(Suppl 1):72-79.
17. Kattamis C., Ladis V., Tsoussis D., et al. Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatr Endocrinol Rev 2004, 2(Suppl 2):267-271.
18. Angelopoulos N.G., Zervas A., Livadas S., et al. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. Diabetes Med 2006, 23:1327-1331.
19. Au W.Y., Lam W.W., Chu W., et al. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica 2008, 93:116-119.
20. Noetzli L.J., Papudesi J., Coates T.D., et al. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009, 114:4021-4026.
21. Armstrong F.D. Thalassemia and learning: neurocognitive functioning in children. Ann NY Acad Sci 2005, 1054:283-289.
22. Metafratzi Z., Argyropoulou M.I., Kiortsis D.N., et al. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br J Radiol 2001, 74:407-410.
23. Stevens R.G., Graubard B.I., Micozzi M.S., et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994, 56:364-369.
24. Fracanzani A.L., Conte D., Fraquelli M., et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001, 33:647-651.
25. Osborne N.J., Gurrin L.C., Allen K.J., et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010, 51:1311-1318.
26. Zacharski L.R., Chow B.K., Howes P.S., et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008, 100:996-1002.
27. Mackey J.R., Desai S., Larratt L., et al. Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature. Bone Marrow Transplant 1997, 19:939-942.
28. Shimada K., Yokozawa T., Atsuta Y., et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 2005, 36:115-121.
29. McDonald G.B., Sullivan K.M., Schuffler M.D., et al. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology 1981, 80:914-921.
30. McDonald G.B., Sullivan K.M., Plumley T.F. Radiographic features of esophageal involvement in chronic graft-versus-host disease. Am J Roentgenol 1984, 142:501-506.
31. Schima W., Pokieser P., Forstinger C., et al. Videofluoroscopy of the pharynx and esophagus in chronic graft-versus-host disease. Abdom Imaging 1994, 19:191-194.
32. Minocha A., Mandanas R.A., Kida M., et al. Bullous esophagitis due to chronic graft-versus-host disease. Am J Gastroenterol 1997, 92:529-530.
33. Patey-Mariaud de Serre N., Reijasse D., Verkarre V., et al. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children. Bone Marrow Transplant 2002, 29:223-230.
34. Akpek G., Chinratanalab W., Lee L.A., et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 2003, 9:46-51.
35. Filipovich A., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
36. McDonald G.B., Bouvier M., Hockenbery D.M., et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998, 115:28-35.
37. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prenisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
38. Iyer R.V., Hahn T., Roy H.N., et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:587-592.
39. Borgaonkar M.R., Duggan P.R., Adams G. Differing clinical manifestations of celiac disease transmitted by bone marrow transplantation. Dig Dis Sci 2006, 51:210-212.
40. McDonald G.B. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010, 51:1450-1460.
41. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
42. Tomas J.F., Pinilla I., Garcia-Buey M.L., et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 2000, 26:649-655.
43. Strasser S.I., Shulman H.M., Flowers M.E., et al. Chronic graft-vs-host disease of the liver: presentation as an acute hepatitis. Hepatology 2000, 32:1265-1271.
44. Malik A.H., Collins J.R.H., Saboorian M.H., et al. Chronic graft versus host disease (GVHD) following hematopoietic cell transplantation (HCT) presenting as an acute hepatitis. Am J Gastroenterol 2001, 96:588-590.
45. Akpek G., Boitnott J.K., Lee L.A., et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002, 100:3903-3907.
46. Shulman H.M., Sharma P., Amos D., et al. A coded histologic study of hepatic graft-versus-host disease after human marrow transplantation. Hepatology 1988, 8:463-470.
47. Strasser S.I., Myerson D., Spurgeon C.L., et al. Hepatitis C virus infection after bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999, 29:1893-1899.
48. Ljungman P., Johansson N., Aschan J., et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995, 86:1614-1618.
49. Strasser S.I., Sullivan K.M., Myerson D., et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999, 93:3259-3266.
50. Peffault de Latour R., Levy V., Asselah T., et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004, 103:1618-1624.
51. Ko C.W., Murakami C., Sekijima J.H., et al. Chemical composition of gallbladder sludge in patients after marrow transplantation. Am J Gastroenterol 1996, 91:1207-1210.
52. Akpek G., Valladares J.L., Lee L., et al. Pancreatic insufficiency in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2001, 27:163-166.
53. Maringhini A., Gertz M.A., DiMagno E.P. Exocrine pancreatic insufficiency after allogeneic bone marrow transplantation. Int J Pancreatol 1995, 17:243-247.
54. Radu B., Allez M., Gornet J.M., et al. Chronic diarrhoea after allogenic bone marrow transplantation. Gut 2005, 54:161-174.
55. Ellis M.J., Parikh C.R., Inrig J.K., et al. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transplant 2008, 8:2378-2390.
56. Choi M., Sun C., Kurian S., et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer 2008, 113:1580-1587.
57. Ando M., Ohashi K., Akiyama H., et al. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol Dial Transplant 2010, 25:278-282.
58. Cohen E.P., Piering W.F., Kabler-Babbit C., et al. End-stage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron 1998, 79:408-4512.
59. Hingorani S., Guthrie K.A., Schoch G., et al. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant 2007, 39:223-229.
60. Miralbell R., Bieri S., Mermillod B., et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 1996, 14:579-585.
61. Weiss A.S., Sandmaier B.M., Storer B., et al. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006, 6:89-94.
62. Steele B., Lirenman D. Acute radiation nephritis and the hemolytic uremic syndrome. Clin Nephrol 1979, 11:272-274.
63. Tarbell N.J., Guinan E.C., Niemeyer C., et al. Late onset of renal dysfunction in survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys 1988, 15:99-104.
64. Guinan E.C., Tarbell N.J., Niemeyer C.M., et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988, 72:451-455.
65. Cohen E., Lawton C., Moulder J. Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron 1995, 70:217-222.
66. Cohen E. Radiation nephropathy after bone marrow transplantation. Kidney Int 2000, 58:903-918.
67. Antignac C., Gubler M.C., Leverger G., et al. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 1989, 35:1336-1344.
68. Rao P. Nephrotic syndrome in patients with peripheral blood stem cell transplant. Am J Kidney Dis 2005, 45:780-785.
69. Ferrara J. Pathogenesis of acute graft versus-host disease:cytokines and cellular effectors. J Hematother Stem Cell Res 2000, 9:299-306.
70. El Seisi S., Gupta R., Clase C.M., et al. Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2003, 9:683-688.
71. Romagnani P., Lazzeri E., Mazzinghi B., et al. Nephrotic syndrome and renal failure after allogeneic stem cell transplantation: novel molecular diagnostic tools for a challenging differential diagnosis. Am J Kidney Dis 2005, 46:550-556.
72. Niculescu F., Niculescu T., Nguyen P., et al. Both apoptosis and complement membrane attack complex deposition are major features of murine acute graft-vs-host disease. Exp Mol Pathol 2005, 79:136-145.
73. Hingorani S.R., Seidel K., Lindner A., et al. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant 2008, 14:1365-1372.
74. Abbate M., Zoja C., Remuzzi G. How does proteinuria cause progressive renal damage?. J Am Soc Nephrol 2006, 17:2974-2984.
75. Cohen E.P., Irving A.A., Drobyski W.R., et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Phys 2008, 70:1546-1551.
76. Yahalom J., Portlock C.S. Long-term cardiac and pulmonary complications of cancer therapy. Hematol Oncol Clin North Am 2008, 22:305-318. vii.
77. Moller T.R., Garwicz S., Barlow L., et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001, 19:3173-3181.
78. Mertens A.C., Yasui Y., Neglia J.P., et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001, 19:3163-3172.
79. van der Pal H.J., van Dalen E.C., Kremer L.C., et al. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev 2005, 31:173-185.
80. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23:2629-2636.
81. Lipshultz S.E., Lipsitz S.R., Mone S.M., et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995, 332:1738-1743.
82. Adams M.J., Lipshultz S.E. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005, 44:600-606.
83. van Dalen E.C., van der Pal H.J., Kok W.E., et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006, 42:3191-3198.
84. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
85. Armenian S.H., Sun C.L., Francisco L., et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008, 26:5537-5543.
86. Armenian S.H., Sun C.L., Kawashima T., et al. Long-term health-related outcomes in survivors of childhood cancer treated with hematopoietic cell transplantation (HCT) versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011, 118:1413-1420.
87. Armenian S.H., Sun C.L., Mills G., et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1138-1144.
88. Wojnowski L., Kulle B., Schirmer M., et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112:3754-3762.
89. Blanco J.G., Leisenring W.M., Gonzalez-Covarrubias V.M., et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008, 112:2789-2795.
90. Henderson I.C., Allegra J.C., Woodcock T., et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989, 7:560-571.
91. Deng S., Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007, 7:129-134.
92. Armenian SH, Ding Y, Sun CL, et al. Genetic susceptibility to anthracycline-related congestive heart failure (A-CHF) in survivors of hematopoietic cell transplantation (HCT) [Abstract]. Bio Blood Marrow Transplant.17;2s:S174.
93. Minotti G., Recalcati S., Menna P., et al. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol 2004, 378:340-361.
94. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
95. Bhatia S., Robison L.L., Francisco L., et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005, 105:4215-4222.
96. Reusch J.E. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002, 90:19G-26G.
97. Trevisan M., Liu J., Bahsas F.B., et al. Syndrome X and mortality: a population-based study. Am J Epidemiol 1998, 148:958-966. Risk Factor and Life Expectancy Research Group.
98. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
99. Taskinen M., Saarinen-Pihkala U.M., Hovi L., et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone marrow transplantation in childhood. Lancet 2000, 356:993-997.
100. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor Study. Blood 2007, 109:1765-1772.
101. Narici M.V., Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull 2010, 95:139-159.
102. Eaton S.B., Cordain L., Sparling P.B. Evolution, body composition, insulin receptor competition, and insulin resistance. Prev Med 2009, 49:283-285.
103. Boirie Y. Physiopathological mechanism of sarcopenia. J Nutr Health Aging 2009, 13:717-723.
104. Baker K.S., Chow E.J., Koves I., et al. Adverse impact of hematopoietic cell transplantation (HCT) on body composition and insulin resistance is associated with increased cardiovascular risk [Abstract]. Biol Blood Marrow Transplant 2011, 17(Suppl 2):S174.
105. Cook S., Weitzman M., Auinger P., et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003, 157:821-827.
106. Genuth S., Alberti K.G., Bennett P., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
107. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004, 109:433-438.
108. Cooke KR, Yanik G. Lung injury following hematopoietic stem cell transplantation. Thomas' Hematopoietic Cell Transplantation. 4th ed.;2009. p. 1456-1472.
109. Baird K, Cooke K, Schultz KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am. 2010;57:297-322.
110. Williams K.M., Chien J.W., Gladwin M.T., et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
111. Duncan C.N., Buonanno M.R., Barry E.V., et al. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:971-975.
112. Yanik G., Cooke K.R. The lung as a target organ of graft-versus-host disease. Semin Hematol 2006, 43:42-52.
113. Yoshihara S., Yanik G., Cooke K.R., et al. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:749-759.
114. Chien JW, Duncan S, Williams KM, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:S106-S114.
115. Hildebrandt GC, Fazekas T, Lawitschka A, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the Consensus Conference on Clinical Practice in Chronic GVHD. Bone Marrow Transplant. 2011. [Epub ahead of print].
116. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
117. Cerveri I., Zoia M.C., Fulgoni P., et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999, 54:131-135.
118. Freudenberger T.D., Madtes D.K., Curtis J.R., et al. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003, 102:3822-3828.
119. Chien J.W., Zhao L.P., Hansen J.A., et al. Genetic variation in bactericidal/permeability: increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006, 107:2200-2207.
120. Hildebrandt G.C., Granell M., Urbano-Ispizua A., et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:67-74.
121. Miyazaki Y., Araki K., Vesin C., et al. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. J Clin Invest 1995, 96:250-259.
122. Yanik GA, Ho VT, Levine JE, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008;112(8):3073-81. Epub 2008 Jul 29.
123. Norman BC, Jacobsohn DA, Williams KM, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant. 2010. [Epub ahead of print].